21 Sep 2016 --- ExcelVite has revealed a new human clinical study uncovering a link between its patented product, EVNol SupraBio, and reduction of LDL-cholesterol, diastolic blood pressure and inflammatory markers such as Interlukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) among metabolic syndrome subjects.
